COVID-19 Anxiety, Uncertainty Fuel China UDCA Frenzy
Options Sought After Sudden Policy Change
Almost overnight, the demand for a little-known liver drug in China has skyrocketed, with makers scrambling to meet surging demand for use in COVID-19. Citizens are looking at every potential way to protect themselves after the country drastically rolled back its strict "COVID Zero" policies, which could result in a huge wave of infections in the world’s most populous nation.
You may also be interested in...
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.
Pfizer is facing a US lawsuit alleging wrongful termination and retaliation against a whistleblower after the company’s former director of Global Compliance Analytics discovered what he viewed to be potential violations in China of the US Foreign Corrupt Practices Act.